WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of 14.11 billion. The enterprise value is 13.82 billion.
| Market Cap | 14.11B |
| Enterprise Value | 13.82B |
Important Dates
The last earnings date was Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -2.80% |
| Shares Change (QoQ) | -1.35% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.50B |
Valuation Ratios
The trailing PE ratio is 30.70.
| PE Ratio | 30.70 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 30.07 |
| EV / Sales | 5.41 |
| EV / EBITDA | 18.11 |
| EV / EBIT | 22.04 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.73 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.89 |
| Debt / FCF | n/a |
| Interest Coverage | 29.10 |
Financial Efficiency
Return on equity (ROE) is 8.82% and return on invested capital (ROIC) is 5.79%.
| Return on Equity (ROE) | 8.82% |
| Return on Assets (ROA) | 5.05% |
| Return on Invested Capital (ROIC) | 5.79% |
| Return on Capital Employed (ROCE) | 9.48% |
| Revenue Per Employee | 203,466 |
| Profits Per Employee | 36,564 |
| Employee Count | 12,740 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 6.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +90.81% in the last 52 weeks. The beta is 0.73, so WuXi Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +90.81% |
| 50-Day Moving Average | 5.88 |
| 200-Day Moving Average | 4.18 |
| Relative Strength Index (RSI) | 57.66 |
| Average Volume (20 Days) | 46,544 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of 2.56 billion and earned 459.79 million in profits. Earnings per share was 0.11.
| Revenue | 2.56B |
| Gross Profit | 1.05B |
| Operating Income | 628.23M |
| Pretax Income | 662.33M |
| Net Income | 459.79M |
| EBITDA | 764.61M |
| EBIT | 628.23M |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
The company has 1.47 billion in cash and 676.78 million in debt, giving a net cash position of 790.50 million.
| Cash & Cash Equivalents | 1.47B |
| Total Debt | 676.78M |
| Net Cash | 790.50M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.23B |
| Book Value Per Share | 1.40 |
| Working Capital | 2.05B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 40.97%, with operating and profit margins of 24.55% and 17.97%.
| Gross Margin | 40.97% |
| Operating Margin | 24.55% |
| Pretax Margin | 25.89% |
| Profit Margin | 17.97% |
| EBITDA Margin | 29.88% |
| EBIT Margin | 24.55% |
| FCF Margin | n/a |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.80% |
| Shareholder Yield | 2.80% |
| Earnings Yield | 3.26% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on December 10, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Dec 10, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |